Antitumor necrosis factor (TNF-a) antibodies in the treatment of renal cell cancer

Related Experiment Video

Updated: Jul 11, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Nick Maisey1

  • 1Department of Academic Oncology, Guys Hospital, London, United Kingdom. nick.maisey@gstt.nhs.uk

Cancer Investigation
|September 14, 2007
PubMed

Insights

Novel therapies for advanced renal cell carcinoma (RCC) are needed. Anti-tumor necrosis factor-alpha (TNF-a) therapy with infliximab showed a 16% response rate in a phase II trial for advanced RCC.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Advanced renal cell carcinoma (RCC) treatment options include kinase inhibitors like sorafenib and sunitinib.
  • There is an unmet need for novel therapeutic strategies in advanced RCC.
  • Tumor necrosis factor-alpha (TNF-a), a cytokine secreted by RCC, has tumor-promoting properties.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of infliximab, a monoclonal antibody targeting TNF-a, in patients with previously treated advanced RCC.

Main Methods:

  • A phase II clinical trial was conducted.
  • Patients with previously treated advanced RCC received infliximab.
  • Tumor response and disease stability were assessed.

Main Results:

  • Infliximab was well tolerated by patients.
  • A 16% objective response rate was observed.
  • An additional 16% of patients achieved disease stability.

Conclusions:

  • Anti-TNF-a therapy, exemplified by infliximab, shows promise as a treatment approach for advanced RCC.
  • Targeting TNF-a may offer a new therapeutic avenue for patients with advanced renal cell carcinoma.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...